SCHEDULE: JPMorgan Chase Discloses 4.0% Stake in Radiopharm Theranostics

JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting a 4.0% beneficial ownership stake in Radiopharm Theranostics Limited as of December 31, 2025.

Summary

• JPMorgan Chase & Co. reported beneficial ownership of 145,679,951 Ordinary Shares, as represented by American Depositary Shares, in Radiopharm Theranostics Limited.
• This ownership represents 4.0% of the class of securities.
• JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 145,679,951 shares.
• The filing is an Amendment No. 2 to a Schedule 13G, with the event date requiring the filing being December 31, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership by a financial institution, indicating a passive investment below the 5% threshold. It does not contain operational or financial performance data for the issuer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding institutional ownership of 4.0% by JPMorgan Chase & Co.

Key Dates

Keywords

Radiopharm Theranostics, JPMorgan Chase, Schedule 13G, Beneficial Ownership, Ordinary Shares, American Depositary Shares, Q79455103